glp-1 mimetics Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide analogues in adults with type 2 diabetes mellitus for glycaemic control Frontiers | Mechanisms of action

Larger and more diverse patient cohorts are needed, lower dosages of semaglutide have to be tested, and follow-ups need to be conducted beyond 26 weeks.

doi: 10.1111/j.1464-5491.2012.03771.x 20 Van der SchuerenBEllisDFaradjiRNAl-OzairiERosenJMathieuC

Step 3: Choose your injection site

Healthcare regulators, including the UKs MHRA and NICE, have carefully reviewed the evidence and continue to endorse GLP-1 receptor agonists, provided patients and prescribers remain aware of the very small potential risk and take appropriate precautions

Studies show that semaglutide can reduce major cardiovascular events by 26% in patients with type 2 diabetes